Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 5Ovarian Neoplasms 2Neoplasm Metastasis 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Gallbladder Neoplasms 1Fibromatosis, Gingival, 2 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 29Gemcitabine 16Cyclophosphamide 14Nivolumab 12Carboplatin 12Capecitabine 11Trastuzumab 9Paclitaxel 9Magnetic Resonance Spectroscopy 8Irinotecan 8Bevacizumab 8Albumin-Bound Paclitaxel 8130-nm albumin-bound paclitaxel 8olaparib 7fludarabine 7Docetaxel 7spartalizumab 6aldesleukin 6Drug Therapy 6Cisplatin 6durvalumab 5atezolizumab 5Standard of Care 5Specimen Handling 5Oxaliplatin 5Biopsy 5sargramostim 4palbociclib 4niraparib 4enzalutamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × seribantumab × Breast × Clear all
NCT04383210 2025-04-03

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Elevation Oncology

Phase 2 Terminated
54 enrolled 11 charts
BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Fibromatosis, Gingival, 2, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Uterine Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡